ANNOUNCEMENT

Take a look at the MedCity ENGAGE program, with expert speakers from leading organizations. Reserve your place today.

Topic: Meridian Bioscience

Meridian’s strep A test gets FDA marketing approval

Meridian’s strep A test gets FDA marketing approval

September 17, 2012 4:35 pm by | 0 Comments

(Reuters) - Meridian Bioscience Inc said its test to detect a common bacterial throat infection received marketing approval in the United States.Meridian said its molecular test can detect Group A ... Read more
Meridian Bioscience in midst of clinical trials for two molecular tests

Meridian Bioscience in midst of clinical trials for two molecular tests

April 26, 2012 11:05 am by | 0 Comments

Meridian Bioscience‘s (NASDAQ:VIVO) has two molecular diagnostic tests in clinical trials, with another test expected to begin trials later in the year.Currently in trials are tests built on the company’s ... Read more
Meridian Bioscience signs molecular diagnostics deal with major GPO

Meridian Bioscience signs molecular diagnostics deal with major GPO

April 13, 2012 10:34 am by | 0 Comments

Meridian Bioscience (NASDAQ:VIVO) has reached a deal to offer discounted prices for two molecular diagnostics tests to members of one of the nation’s largest healthcare group purchasing organizations.Cincinnati-area Meridian hopes ... Read more
Meridian Bioscience gets Australian OK for molecular group B strep test

Meridian Bioscience gets Australian OK for molecular group B strep test

March 21, 2012 9:48 am by | 0 Comments

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus.The test is part of Cincinnati-area Meridian’s illumigene line of molecular diagnostic ... Read more
Meridian Bioscience gets FDA clearance for Legionnaires’ disease test

Meridian Bioscience gets FDA clearance for Legionnaires’ disease test

February 27, 2012 4:02 pm by | 0 Comments

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) has received U.S. Food and Drug Administration clearance for a test to detect bacteria commonly associated with Legionnaires’ disease.Legionnaires’ disease is a severe lung inflammation ... Read more
Meridian Bioscience: Molecular test for Mycoplasma now in clinical trials

Meridian Bioscience: Molecular test for Mycoplasma now in clinical trials

January 25, 2012 9:39 am by | 0 Comments

Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs.The illumigene Mycoplasma test is currently in clinical ... Read more
Meridian Bioscience CEO got 3 percent raise in 2011

Meridian Bioscience CEO got 3 percent raise in 2011

December 29, 2011 12:07 pm by | 0 Comments

Diagnostic test maker Meridian Bioscience‘s (NYSE:VIVO) Chief Executive Jack Kraeutler received a 3 percent increase in compensation this year to $843,000.Here’s how Kraeutler’s 2011 compensation breaks down, according to a ... Read more
FDA approval rounds out Meridian Biosciences’ C. difficile test portfolio

FDA approval rounds out Meridian Biosciences’ C. difficile test portfolio

December 27, 2011 8:54 pm by | 0 Comments

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test.The ImmunoCard C. difficile GDH test has already been launched ... Read more
Meridian Bioscience gets FDA clearance for molecular group B strep test

Meridian Bioscience gets FDA clearance for molecular group B strep test

December 12, 2011 11:40 am by | 0 Comments

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus.The group B strep test is the second in the Cincinnati-area company’s ... Read more
Meridian Bioscience files SEC document to sell shares

Meridian Bioscience files SEC document to sell shares

November 29, 2011 2:05 pm by | 0 Comments

Diagnostic testing company Meridian Bioscience (NASDAQ:VIVO) has filed a regulatory document that gives it the right to sell additional common and preferred shares.The document didn’t specify a dollar amount or ... Read more
Meridian Bioscience to release up to four new illumigene tests in next year

Meridian Bioscience to release up to four new illumigene tests in next year

November 10, 2011 9:49 am by | 0 Comments

Meridian Bioscience (NASDAQ:VIVO) plans to launch up to four new tests from its illumigene molecular diagnostic testing platform over the next year.Cincinnati-area Meridian is betting big on the illumigene platform, ... Read more
Meridian Bioscience bets big on illumigene testing platform

Meridian Bioscience bets big on illumigene testing platform

October 26, 2011 10:22 am by | 0 Comments

Market adoption of Meridian Bioscience’s (NASDAQ:VIVO) new molecular diagnostic testing platform illumigene will go a long way toward determining the company’s future.Cincinnati-area Meridian is betting big on the technology, hoping ... Read more
Meridian Bioscience: Full-year results to come in at bottom of guidance

Meridian Bioscience: Full-year results to come in at bottom of guidance

August 25, 2011 2:15 pm by | 0 Comments

More bad news for investors in diagnostic testing company Meridian Bioscience (NASDAQ:VIVO).The Cincinnati-area company now projects its full-year results to come in at the “lower end” of a range of ... Read more
New C. diff test launched in Europe by Meridian Bioscience

New C. diff test launched in Europe by Meridian Bioscience

August 9, 2011 5:14 pm by | 0 Comments

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe.C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of ... Read more
Meridian Bioscience stock plummets on worsened outlook

Meridian Bioscience stock plummets on worsened outlook

July 21, 2011 11:58 am by | 0 Comments

Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook.Shares of ... Read more